Stocktoria
Spero Therapeutics, Inc. SPRO
Spero Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M | $18.3M | $9.3M | $18.1M | $4.0M | $2.0M | $335,000 |
| R&D expense | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M | $67.0M | $65.8M | $33.9M | $32.9M | $26.3M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M | -$88.0M | -$79.1M | -$63.2M | -$42.8M | -$41.7M | -$33.2M |
| Income tax | $261,000 | $0 | $2.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $8.6M | -$68.6M | $22.8M | — | -$89.8M | -$78.3M | -$60.9M | -$41.7M | -$38.7M | -$25.5M |
| EPS (diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | — | — | — | — | — |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.7M | -$64.3M | -$85.9M | -$50.0M | -$39.6M | -$39.1M | -$29.0M |
| Free cash flow | — | — | — | — | — | -$86.0M | -$50.3M | -$42.1M | -$39.1M | -$29.8M |
| Cash & equivalents | $40.3M | $52.9M | $76.3M | $109.1M | $112.6M | $85.2M | $29.7M | $34.1M | $87.3M | $10.3M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M | $153.5M | $106.1M | $129.0M | $93.5M | $13.8M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M | $21.4M | $31.5M | $13.2M | $8.5M | $7.4M |
| Shareholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M | $132.0M | $74.6M | $115.9M | $85.0M | -$49.2M |
Growth · year-over-year · Revenue CAGR 80.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +39.2% | -53.8% | +94.0% | +193.1% | +95.7% | -48.6% | +357.6% | +100.4% | +490.7% | — |
| Net income growth | — | -400.6% | — | — | — | — | — | — | — | — |
| EPS growth | — | -395.3% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.